Press briefing on the conclusion of the investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events by the Pharmacovigilance Risk Assessment Committee (PRAC)

Date: 18/03/2021
Location: Virtual meeting

Event summary

EMA is holding a virtual press briefing on the conclusion of the evaluation of a safety signal with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) relating to cases of thromboembolic events by EMA’s safety committee (PRAC) on 18 March 2021.


  • Emer Cooke (Executive Director)
  • Sabine Straus (Chair of PRAC
  • Peter Arlett (Head of Data Analytics and Methods Task Force) 

The press briefing will be moderated by Marie-Agnes Heine (Head of Communication). The press briefing will be held in English.

Video recording

Related content

How useful was this page?

Add your rating
6 ratings
1 rating
2 ratings
33 ratings